



Pre-Transplant Essential Data: Disease Classification

CIBMTR Use Only

Sequence Number: _____

Date Received: _____

OMB No: 0915-0310
Expiration Date: 1/31/2020

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0915-0310. Public reporting burden for this collection of information is estimated to average 0.85 hours per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSR Reports Clearance Officer, 5600 Fishers Lane, Room 10-33, Rockville, Maryland, 20857. Expiration date:

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Event date: _____ - _____ - _____

HCT type: *(check all that apply)*

Autologous

Allogeneic, unrelated _____

Allogeneic, related

Product type: *(check all that apply)* _____

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify: _____

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Primary Disease for HCT

1. Date of diagnosis of primary disease for HCT: _____
 YYYY MM DD
2. What was the primary disease for which the HCT was performed?
 - Acute myelogenous leukemia (AML or ANLL) (10) - **Go to question 3**
 - Acute lymphoblastic leukemia (ALL) (20) - **Go to question 85**
 - Acute leukemia of ambiguous lineage and other myeloid neoplasms (80) - **Go to question 146**
 - Chronic myelogenous leukemia (CML) (40) - **Go to question 150**
 - Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias)
(If recipient has transformed to AML, indicate AML as the primary disease) - **Go to question 161**
 - Other leukemia (30) (includes CLL) - **Go to question 255**
 - Hodgkin lymphoma (150) - **Go to question 262**
 - Non-Hodgkin lymphoma (100) - **Go to question 265**
 - Multiple myeloma / plasma cell disorder (PCD) (170) - **Go to question 271**
 - Solid tumors (200) - **Go to question 303**
 - Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)
- **Go to question 305**
 - Inherited abnormalities of erythrocyte differentiation or function (310) - **Go to question 307**
 - Disorders of the immune system (400) - **Go to question 310**
 - Inherited abnormalities of platelets (500) - **Go to question 313**
 - Inherited disorders of metabolism (520) - **Go to question 315**
 - Histiocytic disorders (570) - **Go to question 317**
 - Autoimmune diseases (600) - **Go to question 319**
 - Other disease (900) - **Go to question 327**

Acute Myelogenous Leukemia (AML)

3. Specify the AML classification:

AML with recurrent genetic abnormalities

- AML with t(9;11) (p22.3;q23.3); MLLT3-KMT2A (5)
- AML with t(6;9) (p23;q34.1); DEK-NUP214 (6)
- AML with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM (7)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- AML (megakaryoblastic) with t(1;22) (p13.3;q13.3); RBM15-MKL1 (8)
- AML with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 (281)
- AML with inv(16)(p13.1;1q22) or t(16;16)(p13.1; q22); CBFB-MYH11 (282)
- APL with PML-RARA (283)
- AML with BCR-ABL1 (provisional entity) (3)
- AML with mutated NPM1 (4)
- AML with biallelic mutations of CEBPA (297)
- AML with mutated RUNX1 (provisional entity) (298)
- AML with 11q23 (MLL) abnormalities (i.e., t(4;11), t(6;11), t(9;11), t(11;19)) (284)
- AML with myelodysplasia – related changes (285)
- Therapy related AML (t-AML) (9)

AML, not otherwise specified

- AML, not otherwise specified (280)
- AML, minimally differentiated (286)
- AML without maturation (287)
- AML with maturation (288)
- Acute myelomonocytic leukemia (289)
- Acute monoblastic / acute monocytic leukemia (290)
- Acute erythroid leukemia (erythroid / myeloid and pure erythroleukemia) (291)
- Acute megakaryoblastic leukemia (292)
- Acute basophilic leukemia (293)
- Acute panmyelosis with myelofibrosis (294)
- Myeloid sarcoma (295)
- Myeloid leukemia associated with Down syndrome (299)

3.4 Did AML transform from MDS or MPN?

- Yes – **Also complete MDS Disease Classification questions**
- No

4.5 Is the disease (AML) therapy related?

- Yes
- No
- Unknown

5.6 Did the recipient have a predisposing condition?

- Yes - **Go to question 7**
- No - **Go to question 9**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Unknown - **Go to question 9**

6-7. Specify condition:

- Bloom syndrome - **Go to question 9**
- Down syndrome - **Go to question 9**
- Fanconi anemia - **Go to question 9**
- ~~Neurofibromatosis type 4~~ Dyskeratosis congenita - **Go to question 9**
- Other condition - **Go to question 8**

7-8. Specify other condition: _____

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Labs at diagnosis

9. Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

Yes - **Go to question 10**

No - **Go to question 20**

Unknown - **Go to question 20**

10. Were cytogenetics tested via FISH?

Yes – **Go to question 11**

No - **Go to question 15**

11. Results of tests:

Abnormalities identified – **Go to question 12**

No abnormalities - **Go to question 15**

Specify cytogenetic abnormalities identified at diagnosis:

12. Specify number of distinct cytogenetic abnormalities:

One (1)

Two (2)

Three (3)

Four or more (4 or more)

13. Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

Commented [EL1]: 1.Add some additional instructions around how to answer these for patients that had a prior fanconi, and give examples.

Commented [EL2]: 2.Same format as 2400 Q499
3.
4.Check to see what validations can be done.

Commented [EL3]: 5.For FA patients, clonal abnormalities come and go. May have gotten several bone marrow biopsies. Do we really want every abnormality detected to be reported here?
6.
7.For this question – we're looking to get abnormalities detected since the transformation to AML.
8.
9.With how it's worded, we may be capturing more than needed for patients with a previous fanconi.

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- t(8;21)
- t(9;11)
- t(9;22)
- t(15;17) and variants
- t(16;16)
- del(3q) / 3q-
- del(5q) / 5q-
- del(7q) / 7q-
- del(9q) / 9q-
- del(11q) / 11q-
- del(16q) / 16q-
- del(17q) / 17q-
- del(20q) / 20q-
- del(21q) / 21q-
- inv(3)
- inv(16)
- (11q23) any abnormality
- 12p any abnormality
- Other abnormality - **Go to question 14**

14. Specify other abnormality: _____

15. Were cytogenetics tested via karyotyping?

Yes – **Go to question 16**

No - **Go to question 20**

16. Results of tests:

Abnormalities identified – **Go to question 17**

No evaluable metaphases - **Go to question 20**

No abnormalities - **Go to question 20**

Specify cytogenetic abnormalities identified at diagnosis: _____

17. Specify number of distinct cytogenetic abnormalities: _____

One (1)

Commented [EL4]: 10.Add some additional instructions around how to answer these for patients that had a prior fanconi, and give examples.

Commented [EL5]: 11.Same format as 2400 Q499
12.
13.Check to see what validations can be done.

Commented [EL6]: 14.For FA patients, clonal abnormalities come and go. May have gotten several bone marrow biopsies. Do we really want every abnormality detected to be reported here?

15.
16.For this question – we're looking to get abnormalities detected since the transformation to AML.

17.
18.With how it's worded, we may be capturing more than needed for patients with a previous fanconi.

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Two (2)

Three (3)

Four or more (4 or more)

18. Specify abnormalities: (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

CIBMTR Center Number: _____ CIBMTR Research ID: _____

12p any abnormality

Other abnormality - **Go to question 19**

19. Specify other abnormality: _____

20. Were tests for molecular markers performed (e.g. PCR, NGS)? (at diagnosis)

Yes - **Go to question 21**

No - **Go to question 31**

Unknown - **Go to question 31**

Specify molecular markers identified at diagnosis:

21. CEBPA

Positive - **Go to question 22**

Negative - **Go to question 23**

Not done - **Go to question 23**

22. Specify CEBPA mutation

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

23. FLT3 - D835 point mutation

Positive

Negative

Not done

24. FLT3 - ITD mutation

Positive

Negative

Not done

25. IDH1

Positive

Negative

Not done

26. IDH2

Positive

Negative

CIBMTR Center Number: _____ CIBMTR Research ID: _____

_____ Not done

27. KIT

_____ Positive

_____ Negative

_____ Not done

28. NPM1

_____ Positive

_____ Negative

_____ Not done

29. Other molecular marker

_____ Positive- **Go to question 30**

_____ Negative- **Go to question 30**

_____ Not done- **Go to question 31**

30. Specify other molecular marker: _____

Copy and complete questions 29-30 for multiple molecular markers

Labs at last evaluation prior to the start of the preparative regimen

31. Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

_____ Yes - **Go to question 32**

_____ No - **Go to question 42**

_____ Unknown - **Go to question 42**

32. Were cyteogenetics tested via FISH?

_____ Yes – **Go to question 33**

_____ No - **Go to question 37**

33. Results of tests:

_____ Abnormalities identified – **Go to question 34**

_____ No abnormalities - **Go to question 37**

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

34. Specify number of distinct cytogenetic abnormalities:

_____ One (1)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Two (2)

Three (3)

Four or more (4 or more)

35. Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

CIBMTR Center Number: _____ CIBMTR Research ID: _____

12p any abnormality

Other abnormality - **Go to question 36**

36. Specify other abnormality: _____

37. Were cytogenetics tested via karyotyping?

Yes - **Go to question 38**

No - **Go to question 42**

38. Results of tests:

Abnormalities identified - **Go to question 39**

No evaluable metaphases - **Go to question 42**

No abnormalities - **Go to question 42**

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

39. Specify number of distinct cytogenetic abnormalities:

One (1)

Two (2)

Three (3)

Four or more (4 or more)

40. Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- t(3:3)
- t(6:9)
- t(8:21)
- t(9:11)
- t(9:22)
- t(15:17) and variants
- t(16:16)
- del(3q) / 3q-
- del(5q) / 5q-
- del(7q) / 7q-
- del(9q) / 9q-
- del(11q) / 11q-
- del(16q) / 16q-
- del(17q) / 17q-
- del(20q) / 20q-
- del(21q) / 21q-
- inv(3)
- inv(16)
- (11q23) any abnormality
- 12p any abnormality
- Other abnormality - **Go to question 41**

41. Specify other abnormality: _____

42. Were tests for molecular markers performed (e.g. PCR)? (at last evaluation)

- Yes – **Go to question 43**
- No – **Go to question 55**
- Unknown – **Go to question 55**

Specify molecular markers identified at any time prior to the start of the preparative regimen:

43. CEBPA

- Positive – **Go to question 44**
- Negative - **Go to question 45**
- Not done - **Go to question 45**

44. Specify CEBPA mutation

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Biallelic (homozygous)
- Monoallelic (heterozygous)
- Unknown

45. FLT3 – D835 point mutation

- Positive
- Negative
- Not done

46. FLT3 – ITD mutation

- Positive - *Go to question 47*
- Negative - *Go to question 49*
- Not done - *Go to question 49*

47. FLT3 – ITD allelic ratio

- Known - *Go to question 48*
- Unknown - *Go to question 49*

48. Specify FLT3 - ITD allelic ratio:

Commented [EL7]: 19.0.3-0.7

49. IDH1

- Positive
- Negative
- Not done

50. IDH2

- Positive
- Negative
- Not done

51. KIT

- Positive
- Negative
- Not done

52. NPM1

- Positive
- Negative

CIBMTR Center Number: _____ CIBMTR Research ID: _____

_____ Not done

53. Other molecular marker

_____ Positive- **Go to question 54**

_____ Negative- **Go to question 54**

_____ Not done- **Go to question 55**

54. Specify other molecular marker: _____

Copy and complete questions 53-54 to report multiple other molecular markers

Labs between diagnosis and last evaluation prior to the start of the preparative regimen

55. Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

_____ Yes - **Go to question 56**

_____ No - **Go to question 66**

_____ Unknown - **Go to question 66**

56. Were cytogenetics tested via FISH?

_____ Yes – **Go to question 57**

_____ No - **Go to question 61**

57. Results of tests:

_____ Abnormalities identified – **Go to question 58**

_____ No abnormalities - **Go to question 61**

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

58. Specify number of distinct cytogetic abnormalities:

_____ One (1)

_____ Two (2)

_____ Three (3)

_____ Four or more (4 or more)

59. Specify abnormalities (check all that apply)

_____ -5

_____ -7

_____ -17

_____ -18

_____ -X

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Y
- +4
- +8
- +11
- +13
- +14
- +21
- +22
- t(3;3)
- t(6;9)
- t(8;21)
- t(9;11)
- t(9;22)
- t(15;17) and variants
- t(16;16)
- del(3q) / 3q-
- del(5q) / 5q-
- del(7q) / 7q-
- del(9q) / 9q-
- del(11q) / 11q-
- del(16q) / 16q-
- del(17q) / 17q-
- del(20q) / 20q-
- del(21q) / 21q-
- inv(3)
- inv(16)
- (11q23) any abnormality
- 12p any abnormality
- Other abnormality - **Go to question 60**

60. Specify other abnormality: _____

61. Were cytogenetics tested via karyotyping?

Yes – **Go to question 62**

No - **Go to question 66**

62. Results of tests:

Abnormalities identified – **Go to question 63**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

No evaluable metaphases - ***Go to question 66***

No abnormalities - ***Go to question 66***

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

63. Specify number of distinct cytogenetic abnormalities:

One (1)

Two (2)

Three (3)

Four or more (4 or more)

64. Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

CIBMTR Center Number: _____ CIBMTR Research ID: _____

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality - **Go to question 65**

65. Specify other abnormality: _____

66. Were tests for molecular markers performed (e.g. PCR)? (between diagnosis and last evaluation)

Yes – **Go to question 67**

No – **Go to question 79**

Unknown – **Go to question 79**

Specify molecular markers identified between diagnosis and last evaluation:

67. CEBPA

Positive – **Go to question 68**

Negative - **Go to question 69**

Not done - **Go to question 69**

68. Specify CEBPA mutation

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

69. FLT3 – D835 point mutation

Positive

Negative

Not done

70. FLT3 – ITD mutation

Positive - **Go to question 71**

Negative - **Go to question 73**

Not done - **Go to question 73**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

71. FLT3 – ITD allelic ratio

Known - **Go to question 72**

Unknown - **Go to question 73**

72. Specify FLT3 - ITD allelic ratio:

Commented [EL8]: 20.0.3-0.7

73. IDH1

Positive

Negative

Not done

74. IDH2

Positive

Negative

Not done

75. KIT

Positive

Negative

Not done

76. NPM1

Positive

Negative

Not done

77. Other molecular marker

Positive- **Go to question 78**

Negative- **Go to question 78**

Not done- **Go to question 79**

78. Specify other molecular marker: _____

Copy and complete questions 77-78 to report multiple other molecular markers

CNS Leukemia

CIBMTR Center Number: _____ CIBMTR Research ID: _____

79. Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

- Yes
- No
- Unknown

Commented [EL9]: 21. Need to clarify that this is negative lp. If not tested, need to mark UK, Not tested.

8. _____ Were cytogenetics tested (karyotyping or FISH)?

3. _____
 Yes — **Go to question 10**

4. _____
 No — **Go to question 47**

5. _____
 Unknown — **Go to question 47**

9. _____ Result of tests:

6. _____
Abnormalities identified — **Go to question 11**

7. _____
evaluable metaphases — **Go to question 47**

8. _____
abnormalities — **Go to question 47**

9. _____ Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

10. _____ Monosomy

10. _____ 5

11. _____
 Yes

CIBMTR Center Number: _____ CIBMTR Research ID: _____

12. _____

 No

11. _____ 7

13. _____

 Yes

14. _____

 No

12. _____ 17

15. _____

 Yes

16. _____

 No

13. _____ 18

17. _____

 Yes

18. _____

 No

14. _____ X

19. _____

 Yes

20. _____

 No

15. _____ Y

CIBMTR Center Number: _____ CIBMTR Research ID: _____

21. _____

_____ Yes

22. _____

_____ No

23. _____ **Triso**
my

16. _____ +4

24. _____

_____ Yes

25. _____

_____ No

17. _____ +8

26. _____

_____ Yes

27. _____

_____ No

18. _____ +11

28. _____

_____ Yes

29. _____

_____ No

19. _____ +13

30. _____

_____ Yes

CIBMTR Center Number: _____ CIBMTR Research ID: _____

31. _____

 No

20. _____ +14

32. _____

 Yes

33. _____

 No

21. _____ +21

34. _____

 Yes

35. _____

 No

22. _____ +22

36. _____

 Yes

37. _____

 No

38. _____ Transl
ecation

23. _____ t(3;3)

39. _____

 Yes

40. _____

 No

24. _____ t(6;9)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

41. _____
 Yes

42. _____
 No

25. _____ t(8;21)

43. _____
 Yes

44. _____
 No

26. _____ t(9;11)

45. _____
 Yes

46. _____
 No

27. _____ t(9;22)

47. _____
 Yes

48. _____
 No

28. _____ t(15;17) and variants

49. _____
 Yes

50. _____
 No

CIBMTR Center Number: _____ CIBMTR Research ID: _____

29. _____ t(16;16)

51. _____
_____ Yes

52. _____
_____ No

53. _____ Deletion

30. _____ del(3q)
)/-3q-

54. _____
_____ Yes

55. _____
_____ No

31. _____ del(5q)
)/-5q-

56. _____
_____ Yes

57. _____
_____ No

32. _____ del(7q)
)/-7q-

58. _____
_____ Yes

59. _____
_____ No

CIBMTR Center Number: _____ CIBMTR Research ID: _____

33. _____ del(9q)
)/9q-

60. _____
-_____
-_____ Yes

61. _____
-_____
-_____ No

34. _____ del(11q)
q)/11q-

62. _____
-_____
-_____ Yes

63. _____
-_____
-_____ No

35. _____ del(16q)
q)/16q-

64. _____
-_____
-_____ Yes

65. _____
-_____
-_____ No

36. _____ del(17q)
q)/17q-

66. _____
-_____
-_____ Yes

67. _____
-_____
-_____ No

37. _____ del(20q)
q)/20q-

CIBMTR Center Number: _____ CIBMTR Research ID: _____

68. _____
 Yes

69. _____
 No

38. _____ del(21q)/21q-

70. _____
 Yes

71. _____
 No

72. _____ Inversion

39. _____ inv(3)

73. _____
 Yes

74. _____
 No

40. _____ inv(16)

75. _____
 Yes

76. _____
 No

77. _____ Other

41. _____
(11q23) any abnormality

CIBMTR Center Number: _____ CIBMTR Research ID: _____

78. _____
 Yes

79. _____
 No

42. _____ 12p
any abnormality

80. _____
 Yes

81. _____
 No

43. _____ Compl
ex \geq 3 distinct abnormalities

82. _____
 Yes

83. _____
 No

44. _____ Other
abnormality

84. _____
 Yes **Go to question 46**

85. _____
 No **Go to question 47**

45. _____ Specif
y other abnormality: _____

46. _____ Were
tests for molecular markers performed (e.g. PCR)?
 Yes **Go to question 48**
 No **Go to question 57**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

~~_____ Unknown — Go to question 57~~

Specify molecular markers identified at any time prior to the start of the preparative regimen:

47. _____ CEBPA

_____ Positive

~~_____ Negative~~

~~_____ Not done~~

48. _____ FLT3 — D835 point mutation

_____ Positive

~~_____ Negative~~

~~_____ Not done~~

49. _____ FLT3 — ITD mutation

_____ Positive

~~_____ Negative~~

~~_____ Not done~~

50. _____ IDH1

_____ Positive

~~_____ Negative~~

~~_____ Not done~~

51. _____ IDH2

_____ Positive

~~_____ Negative~~

~~_____ Not done~~

52. _____ KIT

_____ Positive

~~_____ Negative~~

~~_____ Not done~~

53. _____ NPM1

_____ Positive

~~_____ Negative~~

~~_____ Not done~~

CIBMTR Center Number: _____ CIBMTR Research ID: _____

54. _____ Other
molecular marker

~~Positive – Go to question 56~~

~~Negative – Go to question 56~~

~~Not done – Go to question 57~~

55. _____ Specify other molecular marker: _____

Status at transplantation:

56-80. _____ What
was the disease status (based on hematological test results)?

- Primary induction failure – **Go to question 84**
- 1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi and CRp) – **Go to question 81**
- 2nd complete remission – **Go to question 81**
- ≥ 3rd complete remission – **Go to question 81**
- 1st relapse – **Go to question 83**
- 2nd relapse – **Go to question 83**
- ≥ 3rd relapse – **Go to question 83**
- No treatment – **Go to question 84**

57-81. How many cycles of induction therapy were required to achieve 1st complete remission? (e-CR includes CRi, CRp)?

- 1
- 2
- ≥ 3

58. _____ Was the recipient in molecular remission?

3. _____ Yes

4. _____ No

5. _____ Unknown

6. _____ Not applicable

59-82. Was the recipient in remission by flow cytometry?

- Yes – **Go to question 84**
- No – **Go to question 84**
- Unknown – **Go to question 84**
- Not applicable – **Go to question 84**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

60. ~~Was the recipient in cytogenetic remission?~~

7. ~~Yes *Go to question 63*~~

8. ~~No *Go to question 63*~~

9. ~~Unknown *Go to question 63*~~

10. ~~Not applicable *Go to question 63*~~

64.83. Date of most recent relapse: _____
YYY YYY MM DD

62.84. _____ Date
assessed: _____
YYY YYY MM DD **- Go to signature line**

Acute Lymphoblastic Leukemia (ALL)

86.85. Specify ALL classification:

B-lymphoblastic leukemia / lymphoma

- B-lymphoblastic leukemia / lymphoma, NOS (B-cell ALL, NOS) (191)
- B-lymphoblastic leukemia / lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 (192)
- B-lymphoblastic leukemia / lymphoma with t(v;11q23.3); KMT2A rearranged (193)
- B-lymphoblastic leukemia / lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 (194)
- B-lymphoblastic leukemia / lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 (195)
- B-lymphoblastic leukemia / lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH (81)
- B-lymphoblastic leukemia / lymphoma with Hyperdiploidy (51-65 chromosomes) (82)
- B-lymphoblastic leukemia / lymphoma with Hypodiploidy (<45 chromosomes) (83)
- B-lymphoblastic leukemia / lymphoma, BCR-ABL1-like (provisional entity) (94)
- B-lymphoblastic leukemia / lymphoma, with iAMP21 (provisional entity) (95)

T-cell lymphoblastic leukemia / lymphoma

- Early T-cell precursor lymphoblastic leukemia (provisional entity) (96)
- Natural killer (NK)- cell lymphoblastic leukemia / lymphoma (provisional entity) (97)

86. Did the recipient have a predisposing condition?

Commented [EL10]: 22. Divider for paper form only.
Doesn't need to be in FDM

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Yes - ***Go to question 66***

No - ***Go to question 68***

Unknown - ***Go to question 68***

87. Specify condition:

Aplastic anemia - ***Go to question 68 Also complete CIBMTR Form 2028 — APL***

Bloom syndrome - ***Go to question 68***

Down syndrome - ***Go to question 68***

Fanconi anemia - ***Go to question 68 Also complete CIBMTR Form 2029 — FAN***

Other condition - ***Go to question 67***

87-88. Specify other condition: _____

88-89. Were tyrosine kinase inhibitors (i.e. imatinib mesylate) given for pre-HCT therapy at any time prior to start of the preparative regimen?

Yes

No

Laboratory studies at diagnosis:

90. Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

Yes - ***Go to question 70***

No - ***Go to question 81***

Unknown - ***Go to question 81***

91. Were cytogenetics tested via FISH? (at diagnosis)

Yes - ***Go to question 71***

No - ***Go to question 75***

92. Results of tests: (at diagnosis)

Abnormalities identified - ***Go to question 72***

No abnormalities - ***Go to question 75***

Specify cytogenetic abnormalities identified:

93. Specify number of distinct cytogenetic abnormalities:

One (1)

Two (2)

Three (3)

Four or more (4 or more)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

94. Specify abnormalities: (check all that apply)

- 7
- +4
- +8
- +17
- +21
- t(1;19)
- t(2;8)
- t(4;11)
- t(5;14)
- t(8;14)
- t(8;22)
- t(9;22)
- t(10;14)
- t(11;14)
- t(12;21)
- del(6q) / 6q-
- del(9p) / 9p-
- del(12p) / 12p-
- add(14q)
- (11q23) any abnormality
- 9p any abnormality
- 12p any abnormality
- Hyperdiploid (> 50)
- Hypodiploid (< 45)
- Other abnormality – **Go to question 74**

95. Specify other abnormality: _____

96. Were cytogenetics tested via karyotyping? (at diagnosis)

- Yes - **Go to question 76**
- No - **Go to question 80**

97. Results of tests: (at diagnosis)

- Abnormalities identified - **Go to question 77**
- No evaluable metaphases - **Go to question 80**
- No abnormalities - **Go to question 80**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Specify cytogenetic abnormalities identified:

98. Specify number of distinct cytogenetic abnormalities:

- One (1)
- Two (2)
- Three (3)
- Four or more (4 or more)

99. Specify abnormalities: (check all that apply)

- 7
- +4
- +8
- +17
- +21
- t(1;19)
- t(2;8)
- t(4;11)
- t(5;14)
- t(8;14)
- t(8;22)
- t(9;22)
- t(10;14)
- t(11;14)
- t(12;21)
- del(6q) / 6q-
- del(9p) / 9p-
- del(12p) / 12p-
- add(14q)
- (11q23) any abnormality
- 9p any abnormality
- 12p any abnormality
- Hyperdiploid (> 50)
- Hypodiploid (< 45)
- Other abnormality – **Go to question 79**

89-100. Specify other abnormality: _____

90. Were cytogenetics tested (karyotyping or FISH)?

Yes – **Go to question 67**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- No **Go to question 95**
- Unknown **Go to question 95**

91. Results of tests:

- Abnormalities identified **Go to question 68**
- No evaluable metaphases **Go to question 95**
- No abnormalities **Go to question 95**

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Monosomy

92. -7

- Yes
- No

Trisomy

93. +4

- Yes
- No

94. +8

- Yes
- No

95. +17

- Yes
- No

96. +21

- Yes
- No

Translocation

97. t(1;19)

- Yes
- No

CIBMTR Center Number: _____

CIBMTR Research ID: _____

98. ~~t(2;8)~~

~~_____ Yes~~

~~_____ No~~

99. ~~t(4;11)~~

~~_____ Yes~~

~~_____ No~~

100. ~~t(5;14)~~

~~_____ Yes~~

~~_____ No~~

101. ~~t(8;14)~~

~~_____ Yes~~

~~_____ No~~

102. ~~t(8;22)~~

~~_____ Yes~~

~~_____ No~~

103. ~~t(9;22)~~

~~_____ Yes~~

~~_____ No~~

104. ~~t(10;14)~~

~~_____ Yes~~

~~_____ No~~

105. ~~t(11;14)~~

~~_____ Yes~~

~~_____ No~~

106. ~~t(12;21)~~

~~_____ Yes~~

~~_____ No~~

~~_____ **Deletion**~~

107. ~~del(6q)/6q-~~

~~_____ Yes~~

CIBMTR Center Number: _____

CIBMTR Research ID: _____

_____ No

108. ~~del(9p)/9p-~~

_____ Yes

_____ No

109. ~~del(12p)/12p-~~

_____ Yes

_____ No

_____ **Addition**

110. ~~add(14q)~~

_____ Yes

_____ No

_____ **Other**

111. ~~(11q23) any abnormality~~

_____ Yes

_____ No

112. ~~9p any abnormality~~

_____ Yes

_____ No

113. ~~12p any abnormality~~

_____ Yes

_____ No

114. ~~Hyperdiploid (> 50)~~

_____ Yes

_____ No

115. ~~Hypodiploid (< 46)~~

_____ Yes

_____ No

116. ~~Complex - ≥3 distinct abnormalities~~

_____ Yes

CIBMTR Center Number: _____ CIBMTR Research ID: _____

~~_____ No~~

~~117. Other abnormality~~

~~_____ Yes – Go to question 94~~

~~_____ No – Go to question 95~~

~~118. Specify other abnormality: _____~~

~~119-101. _____~~ Were tests for molecular markers performed (e.g. PCR)? (at diagnosis)

~~Yes – Go to question 96~~

~~No – Go to question 100~~

~~Unknown – Go to question 100~~

Specify molecular markers identified at diagnosis any time prior to the start of the preparative regimen:

~~120-102. _____~~ BCR / ABL

~~Positive~~

~~Negative~~

~~Not done~~

~~121-103. _____~~ TEL- AML / AML1

~~Positive~~

~~Negative~~

~~Not done~~

~~122-104. _____~~ Other molecular marker

~~Positive – Go to question 99~~

~~Negative – Go to question 99~~

~~Not done – Go to question 100~~

~~123-105. _____~~ Specify other molecular marker: _____

Copy and complete questions 98-99 for additional molecular markers | _____

Commented [EL11]: 23.Max of 3

Laboratory studies at last evaluation prior to the start of the preparative regimen:

106. Were cytogenetics tested (karyotyping or FISH)? (at last evaluation prior to the start of the preparative regimen)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Yes - **Go to question 86**

No - **Go to question 97**

Unknown - **Go to question 97**

107. Were cytogenetics tested via FISH?

Yes - **Go to question 87**

No - **Go to question 91**

108. Results of tests:

Abnormalities identified - **Go to question 88**

No abnormalities - **Go to question 91**

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

109. Specify number of distinct cytogenetic abnormalities:

One (1)

Two (2)

Three (3)

Four or more (4 or more)

110. Specify abnormalities: (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- del(12p) / 12p-
- add(14q)
- (11q23) any abnormality
- 9p any abnormality
- 12p any abnormality
- Hyperdiploid (> 50)
- Hypodiploid (< 45)
- Other abnormality – **Go to question 90**

111. Specify other abnormality: _____

112. Were cytogenetics tested via karyotyping? (at last evaluation prior to the start of the preparative regimen)

- Yes - **Go to question 92**
- No - **Go to question 97**

113. Results of tests:

- Abnormalities identified - **Go to question 93**
- No evaluable metaphases - **Go to question 97**
- No abnormalities - **Go to question 97**

Commented [EL12]: 24. Need to look at this for analysis.

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

114. Specify number of distinct cytogenetic abnormalities:

- One (1)
- Two (2)
- Three (3)
- Four or more (4 or more)

115. Specify abnormalities: (check all that apply)

- 7
- +4
- +8
- +17
- +21
- t(1;19)
- t(2;8)
- t(4;11)
- t(5;14)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- t(8;14)
- t(8;22)
- t(9;22)
- t(10;14)
- t(11;14)
- t(12;21)
- del(6q) / 6q-
- del(9p) / 9p-
- del(12p) / 12p-
- add(14q)
- (11q23) any abnormality
- 9p any abnormality
- 12p any abnormality
- Hyperdiploid (> 50)
- Hypodiploid (< 45)
- Other abnormality – **Go to question 95**

116. Specify other abnormality: _____

117. Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

- Yes
- No

118. Were tests for molecular markers performed (e.g. PCR)? (at last evaluation prior to the start of the preparative regimen)

- Yes – **Go to question 98**
- No – **Go to question 102**
- Unknown – **Go to question 102**

Specify molecular markers identified at last evaluation prior to the start of the preparative regimen:

119. BCR / ABL

- Positive
- Negative
- Not done

120. TEL-AML / AML1

- Positive
- Negative

CIBMTR Center Number: _____ CIBMTR Research ID: _____

_____ Not done

121. Other molecular marker

_____ Positive – **Go to question 102**

_____ Negative – **Go to question 102**

_____ Not done – **Go to question 103**

122. Specify other molecular marker: _____

Copy and complete questions 100-101 for additional molecular markers

Commented [EL13]: 25.Max of 3

Laboratory studies between diagnosis last evaluation prior to the start of the preparative regimen:

123. Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

_____ Yes - **Go to question 103**

_____ No - **Go to question 114**

_____ Unknown - **Go to question 114**

124. Were cytogenetics tested via FISH? (between diagnosis and the last evaluation)

_____ Yes - **Go to question 104**

_____ No - **Go to question 108**

125. Results of tests: (between diagnosis and the last evaluation)

_____ Abnormalities identified - **Go to question 105**

_____ No abnormalities - **Go to question 108**

Specify cytogenetic abnormalities identified at diagnosis:

126. Specify number of distinct cytogenetic abnormalities:

_____ One (1)

_____ Two (2)

_____ Three (3)

_____ Four or more (4 or more)

127. Specify abnormalities: (check all that apply)

_____ -7

_____ +4

_____ +8

_____ +17

_____ +21

CIBMTR Center Number: _____

CIBMTR Research ID: _____

- t(1;19)
- t(2;8)
- t(4;11)
- t(5;14)
- t(8;14)
- t(8;22)
- t(9;22)
- t(10;14)
- t(11;14)
- t(12;21)
- del(6q) / 6q-
- del(9p) / 9p-
- del(12p) / 12p-
- add(14q)
- (11q23) any abnormality
- 9p any abnormality
- 12p any abnormality
- Hyperdiploid (> 50)
- Hypodiploid (< 45)
- Other abnormality – **Go to question 107**

128. Specify other abnormality: _____

129. Were cytogenetics tested via karyotyping? (between diagnosis and the last evaluation)

Yes - **Go to question 109**

No - **Go to question 114**

130. Results of tests: (between diagnosis and the last evaluation)

Abnormalities identified - **Go to question 110**

No evaluable metaphases - **Go to question 114**

No abnormalities - **Go to question 114**

Specify cytogenetic abnormalities identified at diagnosis:

131. Specify number of distinct cytogenetic abnormalities:

One (1)

Two (2)

Three (3)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Four or more (4 or more)

132. Specify abnormalities: (check all that apply)

- 7
 +4
 +8
 +17
 +21
 t(1;19)
 t(2;8)
 t(4;11)
 t(5;14)
 t(8;14)
 t(8;22)
 t(9;22)
 t(10;14)
 t(11;14)
 t(12;21)
 del(6q) / 6q-
 del(9p) / 9p-
 del(12p) / 12p-
 add(14q)
 (11q23) any abnormality
 9p any abnormality
 12p any abnormality
 Hyperdiploid (> 50)
 Hypodiploid (< 45)
 Other abnormality – **Go to question 112**

133. Specify other abnormality: _____

134. Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes

No

135. Were tests for molecular markers performed (e.g. PCR)? (between diagnosis and last evaluation prior to the start of the preparative regimen)

Yes – **Go to question 115**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

No – ***Go to question 119***

Unknown – ***Go to question 119***

Specify molecular markers identified between diagnosis last evaluation prior to the start of the preparative regimen:

136. BCR / ABL

Positive

Negative

Not done

137. TEL-AML / AML1

Positive

Negative

Not done

138. Other molecular marker

Positive – ***Go to question 118***

Negative – ***Go to question 118***

Not done – ***Go to question 119***

139. Specify other molecular marker: _____

Copy and complete questions 117-118 for additional molecular markers

Commented [EL14]: 26.Max of 3

CNS Leukemia

140. Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen?

Yes

No

Unknown

Status at transplantation:

CIBMTR Center Number: _____ CIBMTR Research ID: _____

~~124-141.~~ _____ What was the disease status (based on hematological test results)?

- Primary induction failure – **Go to question 106**
- 1st complete remission (no previous marrow or extramedullary relapse) – **Go to question 101**
- 2nd complete remission – **Go to question 101**
- ≥ 3rd complete remission – **Go to question 101**
- 1st relapse – **Go to question 105**
- 2nd relapse – **Go to question 105**
- ≥ 3rd relapse – **Go to question 105**
- No treatment – **Go to question 106**

~~125-142.~~ _____ How many cycles of induction therapy were required to achieve 1st complete remissionCR?

- 1
- 2
- ≥ 3

~~126.~~ _____ Was the recipient in molecular remission?

- Yes
- No
- Unknown
- Not applicable

~~127-143.~~ _____ Was the recipient in remission by flow cytometry?

- Yes
- No
- Unknown
- Not applicable

~~128.~~ _____ Was the recipient in cytogenetic remission?

- Yes – **Go to question 106**
- No – **Go to question 106**
- Unknown – **Go to question 106**
- Not applicable – **Go to question 106**

~~129-144.~~ _____ Date of most recent relapse: _____

YYYY MM DD

CIBMTR Center Number: _____ CIBMTR Research ID: _____

~~130-145~~ Date assessed: _____ - **Go to signature line**
YYYY MM DD

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms

- Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification:
 - Blastic plasmacytoid dendritic cell neoplasm (296)– **Go to question 109**
 - Acute undifferentiated leukemia (31) – **Go to question 109**
 - Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84) – **Go to question 109**
 - Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85) – **Go to question 109**
 - Mixed phenotype acute leukemia, B/myeloid, NOS (86) – **Go to question 109**
 - Mixed phenotype acute leukemia, T/myeloid, NOS (87) – **Go to question 109**
 - Other acute leukemia of ambiguous lineage or myeloid neoplasm (88) - **Go to question 108**

2. Specify other acute leukemia of ambiguous lineage or myeloid neoplasm: _____

Status at transplantation:

- What was the disease status (based on hematological test results)?
 - Primary induction failure
 - 1st complete remission (no previous marrow or extramedullary relapse)
 - 2nd complete remission
 - ≥ 3rd complete remission
 - 1st relapse
 - 2nd relapse
 - ≥3rd relapse
 - No treatment

4. Date assessed: _____ - **Go to signature line**
YYYY MM DD

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Chronic Myelogenous Leukemia (CML)

5. Was therapy given prior to this HCT?
- Yes - **Go to questions 112**
 - No - **Go to question 118**
6. Combination chemotherapy
- Yes
 - No
7. Hydroxyurea (Droxia, Hydrea)
- Yes
 - No
8. Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)
- Yes
 - No
9. Interferon- α (Intron, Roferon) (includes PEG)
- Yes
 - No
10. Other therapy
- Yes - **Go to question 117**
 - No - **Go to question 118**
11. Specify other therapy: _____
12. What was the disease status?
- Complete hematologic response (CHR) - **Go to questions 119**
 - Chronic phase - **Go to question 119**
 - Accelerated phase - **Go to question 120**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Blast phase - **Go to question 120**

13. Specify level of response

- No cytogenetic response (No CyR)
- Minimal cytogenetic response
- Minor cytogenetic response
- Partial cytogenetic response (PCyR)
- Complete cytogenetic response (CCyR)
- Major molecular remission (MMR)
- Complete molecular remission (CMR)

14. Number

- 1st
- 2nd
- 3rd or higher

15. Date assessed: _____ - _____ - _____ - **Go to signature line**

YYYY MM DD

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases

16. What was the MDS / MPN subtype at diagnosis? – **If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification questions**

- Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51)
- Refractory anemia with ringed sideroblasts (RARS) (55)
- Refractory anemia with excess blasts-1 (RAEB-1) (61)
- Refractory anemia with excess blasts-2 (RAEB-2) (62)
- Refractory cytopenia with multilineage dysplasia (RCMD) (64)
- Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68)
- Myelodysplastic syndrome with isolated del(5q) (5q- syndrome) (66)
- Myelodysplastic syndrome (MDS), unclassifiable (50)
- Chronic neutrophilic leukemia (165)
- Chronic eosinophilic leukemia, NOS (166)
- Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Polycythemia vera (PCV) (57)
- Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia (MMM), idiopathic myelofibrosis) (167)
- Myeloproliferative neoplasm (MPN), unclassifiable (60)
- Chronic myelomonocytic leukemia (CMML) (54)
- Juvenile myelomonocytic leukemia (JMML/JCML) (no evidence of Ph¹ or BCR/ABL) (36) – **Go to question 167**
- Atypical chronic myeloid leukemia, Ph-/bcr/abl- {CML, NOS} (45) - **Go to question 220**
- Atypical chronic myeloid leukemia, Ph-/bcr unknown {CML, NOS} (46) - **Go to question 220**
- Atypical chronic myeloid leukemia, Ph unknown/bcr- {CML, NOS} (48) - **Go to question 220**
- Atypical chronic myeloid leukemia, Ph unknown/bcr unknown {CML, NOS} (49) - **Go to question 220**
- Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69)

17. Was the disease (MDS/MPN) therapy related?

- Yes
- No
- Unknown

18. Did the recipient have a predisposing condition?

- Yes – **Go to question 125**
- No – **Go to question 127**
- Unknown – **Go to question 127**

19. Specify condition:

- Aplastic anemia – **Go to question 127**
- Bloom syndrome – **Go to question 127**
- Down syndrome – **Go to question 127**
- Fanconi anemia – **Go to question 127**
- Other condition – **Go to question 126**

20. Specify other condition: _____

Laboratory studies at diagnosis of MDS:

21. WBC

- Known
- Unknown

22. _____ • _____ x 10⁹/L (x 10³/mm³)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

x 10⁶/L

23. Hemoglobin

Known

Unknown

24. _____ • _____ g/dL

g/L

mmol/L

25. Was RBC transfused ≤ 30 days before date of test?

Yes

No

26. Platelets

Known

Unknown

27. _____ x 10⁹/L (x 10³/mm³)

x 10⁶/L

28. Were platelets transfused ≤ 7 days before date of test?

Yes

No

29. Neutrophils

Known

Unknown

30. _____ %

31. Blasts in bone marrow

Known

Unknown

32. _____ %

33. Were cytogenetics tested (karyotyping or FISH)?

Yes – **Go to question 140**

No – **Go to question 167**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Unknown – **Go to question 167**

34. Results of tests:

- Abnormalities identified – **Go to question 141**
- No evaluable metaphases – **Go to question 167**
- No abnormalities – **Go to question 167**

Specify abnormalities identified at diagnosis:

35. Specify number of distinct cytogenetic abnormalities:

- One (1)
- Two (2)
- Three (3)
- Four or more (4 or more)

Monosomy

36. –5

- Yes
- No

37.–7

- Yes
- No

38.–13

- Yes
- No

39.–20

- Yes
- No

40.–Y

- Yes
- No

Trisomy

CIBMTR Center Number: _____

CIBMTR Research ID: _____

41. +8

Yes

No

42. +19

Yes

No

Translocation

43. t(1;3)

Yes

No

44. t(2;11)

Yes

No

45. t(3;3)

Yes

No

46. t(3;21)

Yes

No

47. t(6;9)

Yes

No

48. t(11;16)

Yes

No

Deletion

49. del(3q) / 3q-

Yes

No

50. del(5q) / 5q-

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Yes –

No

51.del(7q) / 7q-

Yes

No

52.del(9q) / 9q-

Yes

No

53.del(11q) / 11q-

Yes

No

54.del(12p) / 12p-

Yes

No

55.del(13q) / 13q-

Yes

No

56. del(20q) / 20q-

Yes

No

Inversion

57. inv(3)

Yes

No

Other

58. i17q

Yes

No

59. Other abnormality

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Yes – **Go to question 166**

No – **Go to question 167**

60. Specify other abnormality: _____

61. Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

Yes – **Go to question 168**

No – **Go to question 171**

62. Specify the MDS / MPN subtype after transformation:

Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51) – **Go to question 169**

Refractory anemia with ringed sideroblasts (RARS) (55) – **Go to question 169**

Refractory anemia with excess blasts-1 (RAEB-1) (61) – **Go to question 169**

Refractory anemia with excess blasts-2 (RAEB-2) (62) – **Go to question 169**

Refractory cytopenia with multilineage dysplasia (RCMD) (64) – **Go to question 169**

Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68) – **Go to question 169**

Myelodysplastic syndrome with isolated del(5q) (5q- syndrome) (66) – **Go to question 169**

Myelodysplastic syndrome (MDS), unclassifiable (50) – **Go to question 169**

Chronic neutrophilic leukemia (165) – **Go to question 169**

Chronic eosinophilic leukemia, NOS (166) – **Go to question 169**

Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58) – **Go to question 169**

Polycythemia vera (PCV) (57) – **Go to question 169**

Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia (MMM), idiopathic myelofibrosis) (167) – **Go to question 169**

Myeloproliferative neoplasm (MPN), unclassifiable (60) – **Go to question 169**

Chronic myelomonocytic leukemia (CMML) (54) – **Go to question 169**

Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69) – **Go to question 169**

Transformed to AML (70) – **Go to question 170**

63. Specify the date of the most recent transformation: _____ – _____ – _____ - **Go to question 171**

64. Date of MDS diagnosis: _____ - _____ - _____ - **Go to signature line**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Laboratory studies at last evaluation prior to the start of the preparative regimen:

65. WBC

- Known
- Unknown

66. _____ • _____ x 10⁹/L (x 10³/mm³)
 x 10⁶/L

67. Hemoglobin

- Known
- Unknown

68. _____ • _____ g/dL
 g/L
 mmol/L

69. Was RBC transfused ≤ 30 days before date of test?

- Yes
- No

70. Platelets

- Known
- Unknown

71. _____ x 10⁹/L (x 10³/mm³)
 x 10⁶/L

72. Were platelets transfused ≤ 7 days before date of test?

- Yes
- No

73. Neutrophils

- Known
- Unknown

74. _____%

75. Blasts in bone marrow

- Known

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Unknown

76. _____ %

77. Were cytogenetics tested (karyotyping or FISH)?

Yes – **Go to question 184**

No – **Go to question 211**

Unknown – **Go to question 211**

78. Results of tests:

Abnormalities identified – **Go to question 185**

No evaluable metaphases – **Go to question 211**

No abnormalities – **Go to question 211**

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

79. Specify number of distinct cytogenetic abnormalities:

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Monosomy

80. –5

Yes

No

81.–7

Yes

No

82.–13

Yes

No

83.–20

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Yes

No

84. -Y

Yes

No

Trisomy

85. +8

Yes

No

86. +19

Yes

No

Translocation

87. t(1;3)

Yes

No

88. t(2;11)

Yes

No

89. t(3;3)

Yes

No

90. t(3;21)

Yes

No

91. t(6;9)

Yes

No

92. t(11;16)

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Yes

No

Deletion

93. del(3q) / 3q-

Yes

No

94. del(5q) / 5q-

Yes

No

95. del(7q) / 7q-

Yes

No

96. del(9q) / 9q-

Yes

No

97. del(11q) / 11q-

Yes

No

98. del(12p) / 12p-

Yes

No

99. del(13q) / 13q-

Yes

No

100. del(20q) / 20q-

Yes

No

Inversion

101. inv(3)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Yes

No

Other

102. i17q

Yes

No

103. Other abnormality

Yes – **Go to question 210**

No – **Go to question 211**

104. Specify other abnormality: _____

Status at transplantation:

105. What was the disease status?

- Complete remission (CR)** – requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: $< 5\%$ myeloblasts with normal maturation of all cell lines * peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC $\geq 1000/\text{mm}^3$ without myeloid growth factor support; platelets $\geq 100 \times 10^9/\text{L}$ without thrombopoietic support; 0% blasts - **Go to question 215**
- Hematologic improvement (HI)** – requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to determine HI response: * HI-E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0 , reduction in RBC units transfused in 8 weeks by ≥ 4 units compared to the pre-treatment transfusion number in 8 weeks * HI-P – for pre-treatment platelet count of $> 20 \times 10^9/\text{L}$, platelet absolute increase of $\geq 30 \times 10^9/\text{L}$; for pre-treatment platelet count of $< 20 \times 10^9/\text{L}$, platelet absolute increase of $\geq 20 \times 10^9/\text{L}$ and $\geq 100\%$ from pre-treatment level * HI-N – neutrophil count increase of $\geq 100\%$ from pre-treatment level and an absolute increase of $\geq 500/\text{mm}^3$ - **Go to question 212**
- No response (NR) / stable disease (SD)** – does not meet the criteria for at least HI, but no evidence of disease progression - **Go to question 215**
- Progression from hematologic improvement (Prog from HI)** – requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): * $\geq 50\%$ reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion dependence - **Go to question 213**
- Relapse from complete remission (Rel from CR)** – requires at least one of the following: * return to pre-treatment bone marrow blast percentage * decrease of $\geq 50\%$ from maximum response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy - **Go to question 214**
- Not assessed** - **Go to signature line**

106. Specify the cell line examined to determine HI status:

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- HI-E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for $Hgb \leq 9.0$, reduction in RBC units transfused in 8 weeks by ≥ 4 units compared to the pre-treatment transfusion number in 8 weeks - **Go to question 215**
- HI-P – for pre-treatment platelet count of $> 20 \times 10^9/L$, platelet absolute increase of $\geq 30 \times 10^9/L$; for pre-treatment platelet count of $< 20 \times 10^9/L$, platelet absolute increase of $\geq 20 \times 10^9/L$ and $\geq 100\%$ from pre-treatment level – **Go to question 215**
- HI-N – neutrophil count increase of $\geq 100\%$ from pre-treatment level and an absolute increase of $\geq 500/mm^3$ - **Go to question 215**

107. Date of progression: _____ - **Go to question 215**
 YYYY MM DD

108. Date of relapse: _____ - **Go to question 215**
 YYYY MM DD

109. Date assessed: _____ - **Go to signature line**
 YYYY MM DD

Other Leukemia (OL)

110. Specify the other leukemia classification:

- Chronic lymphocytic leukemia (CLL), NOS (34) - **Go to question 218**
- Chronic lymphocytic leukemia (CLL), B-cell / small lymphocytic lymphoma (SLL) (71) - **Go to question 218**
- Hairy cell leukemia (35) - **Go to question 221**
- Hairy cell leukemia variant (75) - **Go to question 221**
- Monoclonal B-cell lymphocytosis (76) – **Go to signature line**
- Prolymphocytic leukemia (PLL), NOS (37) - **Go to question 218**
- PLL, B-cell (73) - **Go to question 218**
- PLL, T-cell (74) - **Go to question 218**
- Other leukemia, NOS (30) - **Go to question 220**
- Other leukemia (39) - **Go to question 217**

111. Specify other leukemia: _____ – **Go to question 220**

112. Was any 17p abnormality detected?

- Yes – **If disease classification is CLL, go to question 219. If PLL, go to question 221.**
- No

CIBMTR Center Number: _____ CIBMTR Research ID: _____

113. Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?

- Yes – **Go to question 226**– Also complete **NHL Disease Classification** questions
- No – **Go to question 221**

Status at transplantation:

114. What was the disease status? (Atypical CML)

- Primary induction failure – **Go to question 222**
- 1st complete remission (no previous bone marrow or extramedullary relapse) – **Go to question 222**
- 2nd complete remission – **Go to question 222**
- ≥ 3rd complete remission – **Go to question 222**
- 1st relapse – **Go to question 222**
- 2nd relapse – **Go to question 222**
- ≥ 3rd relapse – **Go to question 222**
- No treatment – **Go to signature line**

115. What was the disease status? (CLL, PLL, Hairy cell leukemia)

- Complete remission (CR) – **Go to question 222**
- Partial remission (PR) – **Go to question 222**
- Stable disease (SD) – **Go to question 222**
- Progressive disease (Prog) – **Go to question 222**
- Untreated - **Go to question 222**
- Not assessed - **Go to signature line**

116. Date assessed: _____ - **Go to signature line**
 YYYY MM DD

Hodgkin Lymphoma

117. Specify Hodgkin lymphoma classification:

- Nodular lymphocyte predominant Hodgkin lymphoma (155)
- Lymphocyte-rich (151)
- Nodular sclerosis (152)
- Mixed cellularity (153)
- Lymphocyte depleted (154)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Hodgkin lymphoma, NOS (150)

Status at transplantation:

118. What was the disease status?

- Disease untreated
- PIF res - Primary induction failure – resistant: NEVER in COMPLETE remission but with stable or progressive disease on treatment.
- PIF sen / PR1 - Primary induction failure – sensitive: NEVER in COMPLETE remission but with partial remission on treatment.
- PIF unk - Primary induction failure – sensitivity unknown
- CR1 - 1st complete remission: no bone marrow or extramedullary relapse prior to transplant
- CR2 - 2nd complete remission
- CR3+ - 3rd or subsequent complete remission
- REL1 unt - 1st relapse – untreated; includes either bone marrow or extramedullary relapse
- REL1 res - 1st relapse – resistant: stable or progressive disease with treatment
- REL1 sen - 1st relapse – sensitive: partial remission (if complete remission was achieved, classify as CR2)
- REL1 unk - 1st relapse – sensitivity unknown
- REL2 unt - 2nd relapse – untreated: includes either bone marrow or extramedullary relapse
- REL2 res - 2nd relapse – resistant: stable or progressive disease with treatment
- REL2 sen - 2nd relapse – sensitive: partial remission (if complete remission achieved, classify as CR3+)
- REL2 unk - 2nd relapse – sensitivity unknown
- REL3+ unt - 3rd or subsequent relapse – untreated; includes either bone marrow or extramedullary relapse
- REL3+ res - 3rd or subsequent relapse – resistant: stable or progressive disease with treatment
- REL3+ sen - 3rd or subsequent relapse – sensitive: partial remission (if complete remission achieved, classify as CR3+)
- REL3+ unk - 3rd relapse or greater – sensitivity unknown

119. Date assessed: _____ - _____ - _____ - **Go to signature line**
 YYYY MM DD

Non-Hodgkin Lymphoma

120. Specify Non-Hodgkin lymphoma classification:

- Splenic marginal zone B-cell lymphoma (124)
- Extranodal marginal zone B-cell lymphoma of mucosal associated lymphoid tissue type (MALT) (122)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Nodal marginal zone B-cell lymphoma (\pm monocytoid B-cells) (123)
- Follicular, predominantly small cleaved cell (Grade I follicle center lymphoma) (102)
- Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma) (103)
- Follicular, predominantly large cell (Grade IIIA follicle center lymphoma) (162)
- Follicular, predominantly large cell (Grade IIIB follicle center lymphoma) (163)
- Follicular (grade unknown) (164)
- Mantle cell lymphoma (115)
- Intravascular large B-cell lymphoma (136)
- Primary mediastinal (thymic) large B-cell lymphoma (125)
- Primary effusion lymphoma (138)
- Diffuse, large B-cell lymphoma — NOS (107)
- Burkitt lymphoma (111)
- B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (140)
- B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin Lymphoma (149)
- T-cell / histiocytic rich large B-cell lymphoma (120)
- Primary diffuse large B-cell lymphoma of the CNS (118)
- Waldenstrom macroglobulinemia / Lymphoplasmacytic lymphoma (173)
- Other B-cell lymphoma (129) – **Go to question 227**
- Extranodal NK / T-cell lymphoma, nasal type (137)
- Enteropathy-type T-cell lymphoma (133)
- Hepatosplenic T-cell lymphoma (145)
- Subcutaneous panniculitis-like T-cell lymphoma (146)
- Mycosis fungoides (141)
- Sezary syndrome (142)
- Primary cutaneous CD30+ T-cell lymphoproliferative disorders [Primary cutaneous anaplastic large-cell lymphoma (C-ALCL), lymphoid papulosis] (147)
- Peripheral T-cell lymphoma (PTCL), NOS (130)
- Angioimmunoblastic T-cell lymphoma (131)
- Anaplastic large-cell lymphoma (ALCL), ALK positive (143)
- Anaplastic large-cell lymphoma (ALCL), ALK negative (144)
- T-cell large granular lymphocytic leukemia (126)
- Aggressive NK-cell leukemia (27)
- Adult T-cell lymphoma / leukemia (HTLV1 associated) (134)
- Other T-cell / NK-cell lymphoma (139) – **Go to question 227**

121. Specify other lymphoma: _____

122. Is the non-Hodgkin lymphoma histology reported at diagnosis a transformation from CLL?

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Yes – **Go to question 230- Also complete CLL Disease Classification questions**

No - **Go to question 229**

123. Is the non-Hodgkin lymphoma histology reported a transformation from, or was it diagnosed at the same time as another lymphoma (not CLL)?

Yes

No

Status at transplantation:

124. What was the disease status?

Disease untreated

PIF res - Primary induction failure – resistant: NEVER in COMPLETE remission but with stable or progressive disease on treatment.

PIF sen / PR1 - Primary induction failure – sensitive: NEVER in COMPLETE remission but with partial remission on treatment.

PIF unk - Primary induction failure – sensitivity unknown

CR1 - 1st complete remission: no bone marrow or extramedullary relapse prior to transplant

CR2 - 2nd complete remission

CR3+ - 3rd or subsequent complete remission

REL1 unt - 1st relapse – untreated; includes either bone marrow or extramedullary relapse

REL1 res - 1st relapse – resistant: stable or progressive disease with treatment

REL1 sen - 1st relapse – sensitive: partial remission (if complete remission was achieved, classify as CR2)

REL1 unk - 1st relapse – sensitivity unknown

REL2 unt - 2nd relapse – untreated: includes either bone marrow or extramedullary relapse

REL2 res - 2nd relapse – resistant: stable or progressive disease with treatment

REL2 sen - 2nd relapse – sensitive: partial remission (if complete remission achieved, classify as CR3+)

REL2 unk - 2nd relapse – sensitivity unknown

REL3+ unt - 3rd or subsequent relapse – untreated; includes either bone marrow or extramedullary relapse

REL3+ res - 3rd or subsequent relapse – resistant: stable or progressive disease with treatment

REL3+ sen - 3rd or subsequent relapse – sensitive: partial remission (if complete remission achieved, classify as CR3+)

REL3+ unk - 3rd relapse or greater – sensitivity unknown

125. Date assessed: _____ - **Go to signature line**

YYYY

MM

DD

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Multiple Myeloma / Plasma Cell Disorder (PCD)

126. Specify the multiple myeloma/plasma cell disorder (PCD) classification:

- Multiple myeloma-IgG (181) - **Go to questions 234**
- Multiple myeloma-IgA (182) - **Go to questions 234**
- Multiple myeloma-IgD (183) - **Go to questions 234**
- Multiple myeloma-IgE (184) - **Go to questions 234**
- Multiple myeloma-IgM (not Waldenstrom macroglobulinemia) (185) - **Go to questions 234**
- Multiple myeloma-light chain only (186) - **Go to questions 234**
- Multiple myeloma-non-secretory (187) - **Go to questions 235**
- Plasma cell leukemia (172) - **Go to question 240**
- Solitary plasmacytoma (no evidence of myeloma) (175) - **Go to question 240**
- Amyloidosis (174) - **Go to question 240**
- Osteosclerotic myeloma / POEMS syndrome (176) - **Go to questions 240**
- Light chain deposition disease (177) - **Go to questions 240**
- Other plasma cell disorder (179) - **Go to question 233**

127. Specify other plasma cell disorder: _____ - **Go to question 240**

128. Light chain

- kappa
- lambda

129. What was the Durie-Salmon staging (at diagnosis)?

- Stage I (All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma only; low M-component production rates IgG < 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4g/24h) – **Go to questions 236**
- Stage II (Fitting neither Stage I or Stage III) – **Go to questions 236**
- Stage III (One of more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates IgG >7g/dL, IgA > 5g/dL; Bence Jones protein >12g/24h) – **Go to questions 236**
- Unknown – **Go to questions 237**

130. What was the Durie-Salmon sub classification (at diagnosis)?

- A - relatively normal renal function (serum creatinine < 2.0 mg/dL)
- B - abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

I.S.S.:

CIBMTR Center Number: _____ CIBMTR Research ID: _____

131. Serum β 2-microglobulin: _____ • _____ μ g/dL
 mg/L
 nmol/L

132. Serum albumin: _____ • _____ g/dL
 g/L

133. Stage
 1 (β 2-mic < 3.5, S. albumin \geq 3.5)
 2 (β 2-mic 3.5–< 5.5, S. albumin —)
 3 (β 2-mic \geq 5.5; S. albumin —)

134. Were cytogenetics tested (karyotyping or FISH)?
 Yes – **Go to questions 241**
 No – **Go to question 262**
 Unknown – **Go to question 262**

135. Results of tests:
 Abnormalities identified – **Go to question 242**
 No evaluable metaphases – **Go to question 262**
 No abnormalities – **Go to question 262**

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

136. +3
 Yes
 No

137. +5
 Yes
 No

138. +7
 Yes
 No

139. +9

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Yes

No

140. +11

Yes

No

141. +15

Yes

No

142. +19

Yes

No

Translocation

143. t(4;14)

Yes

No

144. t(6;14)

Yes

No

145. t(11;14)

Yes

No

146. t(14;16)

Yes

No

147. t(14;20)

Yes

No

Deletion

148. del (13)/13q-

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Yes

No

149. del (17)/17p-

Yes

No

Other

150. Hyperdiploid (>50)

Yes

No

151. Hypodiploid (<46)

Yes

No

152. Any abnormality at 1q

Yes

No

153. Any abnormality at 1p

Yes

No

154. Other abnormality

Yes

No

155. Specify other abnormality: _____

Status at transplantation:

156. What was the disease status?

Stringent complete remission (sCR). - CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the κ/λ ratio. An abnormal κ/λ ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is κ/λ of $> 4:1$ or $< 1:2$.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR requirements. - **Go to question 263**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Complete remission (CR)** — negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone marrow (confirmation with repeat bone marrow biopsy not needed). CR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy CR requirements. - **Go to question 263**
- Near complete remission (nCR)** — serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in bone marrow. nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. - **Go to question 263**
- Very good partial remission (VGPR)** — serum and urine M-protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours. VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements. - **Go to question 263**
- Partial remission (PR)** — ≥ 50% reduction in serum M-protein, and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: • serum M-protein ≥ 1 g/dL. Urine M-protein ≥ 200 mg/24 hours • serum free light chain assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. - **Go to question 263**
- Stable disease (SD)** — not meeting the criteria for CR, VGPR, PR or PD. SD requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD requirements. - **Go to question 263**
- Progressive disease (PD)** — requires any one or more of the following: Increase of ≥ 25% from baseline in: serum M-component and/or (absolute increase ≥ 0.5 g/dL) (for progressive disease, serum M-component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M-component is ≥ 5 g/dL). Urine M-component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase > 10 mg/dL). Bone marrow plasma cell percentage (absolute percentage ≥ 10%) (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder PD requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy - **Go to question 263**
- Relapse from CR (Rel) (untreated)** — requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis development of ≥ 5% plasma cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia). Rel requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy. - **Go to question 263**
- Unknown** - **Go to signature line**
- Not applicable (Amyloidosis with no evidence of myeloma)** - **Go to signature line**

157. Date assessed: _____ — _____ — _____ - **Go to signature line**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

YYYY MM DD

Solid Tumors

158. Specify the solid tumor classification:

- Breast cancer (250)
- Lung, small cell (202)
- Lung, non-small cell (203)
- Lung, not otherwise specified (230)
- Germ cell tumor, extragonadal (225)
- Testicular (210)
- Ovarian (epithelial) (214)
- Bone sarcoma (excluding Ewing family tumors) (273)
- Ewing family tumors of bone (including PNET) (275)
- Ewing family tumors, extrasosseous (including PNET) (276)
- Fibrosarcoma (244)
- Hemangiosarcoma (246)
- Leiomyosarcoma (242)
- Liposarcoma (243)
- Lymphangio sarcoma (247)
- Neurogenic sarcoma (248)
- Rhabdomyosarcoma (232)
- Synovial sarcoma (245)
- Soft tissue sarcoma (excluding Ewing family tumors) (274)
- Central nervous system tumor, including CNS PNET (220)
- Medulloblastoma (226)
- Neuroblastoma (222)
- Head / neck (201)
- Mediastinal neoplasm (204)
- Colorectal (228)
- Gastric (229)
- Pancreatic (206)
- Hepatobiliary (207)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Prostate (209)
- External genitalia (211)
- Cervical (212)
- Uterine (213)
- Vaginal (215)
- Melanoma (219)
- Wilm tumor (221)
- Retinoblastoma (223)
- Thymoma (231)
- Renal cell (208)
- Other solid tumor (270) – **Go to question 265**
- Solid tumor, not otherwise specified (200)

159. Specify other solid tumor: _____

- **Go to signature line**

Severe Aplastic Anemia

160. Specify the severe aplastic anemia classification:

- Acquired severe aplastic anemia, not otherwise specified (301)
- Acquired SAA secondary to hepatitis (302)
- Acquired SAA secondary to toxin / other drug (303)
- Acquired amegakaryocytosis (not congenital) (304)
- Acquired pure red cell aplasia (not congenital) (306)
- Dyskeratosis congenita (307)
- Other acquired cytopenic syndrome (309) – **Go to question 267**

161. Specify other acquired cytopenic syndrome: _____

- **Go to signature line**

Inherited Abnormalities of Erythrocyte Differentiation or Function

162. Specify the inherited abnormalities of erythrocyte differentiation or function classification:

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Paroxysmal nocturnal hemoglobinuria (PNH) (56)
- Shwachman-Diamond (305)
- Diamond-Blackfan anemia (pure red cell aplasia) (312)
- Other constitutional anemia (319) – **Go to question 269**
- Fanconi anemia (311) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease).
- Sickle thalassemia (355)
- Sickle cell disease (356)
- Beta thalassemia major (357)
- Other hemoglobinopathy (359) – **Go to question 270**

163. Specify other constitutional anemia: _____

164. Specify other hemoglobinopathy: _____

- **Go to signature line**

Disorders of the Immune System

165. Specify disorder of immune system classification:

- Adenosine deaminase (ADA) deficiency / severe combined immunodeficiency (SCID) (401)
- Absence of T and B cells SCID (402)
- Absence of T, normal B cell SCID (403)
- Omenn syndrome (404)
- Reticular dysgenesis (405)
- Bare lymphocyte syndrome (406)
- Other SCID (419) – **Go to question 272**
- SCID, not otherwise specified (410)
- Ataxia telangiectasia (451)
- HIV infection (452)
- DiGeorge anomaly (454)
- Common variable immunodeficiency (457)
- Leukocyte adhesion deficiencies, including GP180, CD-18, LFA and WBC adhesion deficiencies (459)
- Kostmann agranulocytosis (congenital neutropenia) (460)
- Neutrophil actin deficiency (461)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Cartilage-hair hypoplasia (462)
- CD40 ligand deficiency (464)
- Other immunodeficiencies (479) – **Go to question 273**
- Immune deficiency, not otherwise specified (400)
- Chediak-Higashi syndrome (456)
- Griscelli syndrome type 2 (465)
- Hermansky-Pudlak syndrome type 2 (466)
- Chronic granulomatous disease (455)
- Wiskott-Aldrich syndrome (453)
- X-linked lymphoproliferative syndrome (458)

166. Specify other SCID: _____

167. Specify other immunodeficiency: _____

- **Go to signature line**

Inherited Abnormalities of Platelets

168. Specify inherited abnormalities of platelets classification:

- Congenital amegakaryocytosis / congenital thrombocytopenia (501)
- Glanzmann thrombasthenia (502)
- Other inherited platelet abnormality (509) – **Go to question 275**

169. Specify other inherited platelet abnormality: _____

- **Go to signature line**

Inherited Disorders of Metabolism

170. Specify inherited disorders of metabolism classification:

- Osteopetrosis (malignant infantile osteopetrosis) (521)

Leukodystrophies

- Metachromatic leukodystrophy (MLD) (542)
- Adrenoleukodystrophy (ALD) (543)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Krabbe disease (globoid leukodystrophy) (544)
- Lesch-Nyhan (HGPRT deficiency) (522)
- Neuronal ceroid lipofuscinosis (Batten disease) (523)

Mucopolysaccharidoses

- Hurler syndrome (IH) (531)
- Scheie syndrome (IS) (532)
- Hunter syndrome (II) (533)
- Sanfilippo (III) (534)
- Morquio (IV) (535)
- Maroteaux-Lamy (VI) (536)
- β -glucuronidase deficiency (VII) (537)
- Mucopolysaccharidosis (V) (538)
- Mucopolysaccharidosis, not otherwise specified (530)

Mucolipidoses

- Gaucher disease (541)
- Niemann-Pick disease (545)
- I-cell disease (546)
- Wolman disease (547)
- Glucose storage disease (548)
- Mucolipidoses, not otherwise specified (540)

Polysaccharide hydrolase abnormalities

- Aspartyl glucosaminidase (561)
- Fucosidosis (562)
- Mannosidosis (563)
- Polysaccharide hydrolase abnormality, not otherwise specified (560)
- Other inherited metabolic disorder (529) – **Go to question 277**
- Inherited metabolic disorder, not otherwise specified (520)

171. Specify other inherited metabolic disorder: _____

- **Go to signature line**

Histiocytic disorders

172. Specify histiocytic disorder classification:

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Hemophagocytic lymphohistiocytosis (HLH) (571)
- Langerhans cell histiocytosis (histiocytosis-X) (572)
- Hemophagocytosis (reactive or viral associated) (573)
- Malignant histiocytosis (574)
- Other histiocytic disorder (579) – **Go to question 279**
- Histiocytic disorder, not otherwise specified (570)

173. Specify other histiocytic disorder: _____

- **Go to signature line**

Autoimmune Diseases

174. Specify autoimmune disease classification:

Arthritis

- Rheumatoid arthritis (603)
- Psoriatic arthritis / psoriasis (604)
- Juvenile idiopathic arthritis (JIA): systemic (Stills disease) (640)
- Juvenile idiopathic arthritis (JIA): oligoarticular (641)
- Juvenile idiopathic arthritis (JIA): polyarticular (642)
- Juvenile idiopathic arthritis (JIA): other (643) **Go to question 282**
- Other arthritis (633) – **Go to question 281**

Multiple sclerosis

- Multiple sclerosis (602)

Connective tissue diseases

- Systemic sclerosis (scleroderma) (607)
- Systemic lupus erythematosus (SLE) (605)
- Sjögren syndrome (608)
- Polymyositis / dermatomyositis (606)
- Antiphospholipid syndrome (614)
- Other connective tissue disease (634) – **Go to question 283**

Vasculitis

- Wegener granulomatosis (610)
- Classical polyarteritis nodosa (631)
- Microscopic polyarteritis nodosa (632)

CIBMTR Center Number: _____ CIBMTR Research ID: _____

- Churg-Strauss (635)
- Giant cell arteritis (636)
- Takayasu (637)
- Behcet syndrome (638)
- Overlap necrotizing arteritis (639)
- Other vasculitis (611) – **Go to question 284**

Other neurological autoimmune diseases

- Myasthenia gravis (601)
- Other autoimmune neurological disorder (644) – **Go to question 285**

Hematological autoimmune diseases

- Idiopathic thrombocytopenic purpura (ITP) (645)
- Hemolytic anemia (646)
- Evan syndrome (647)
- Other autoimmune cytopenia (648) – **Go to question 286**

Bowel diseases

- Crohn's disease (649)
- Ulcerative colitis (650)
- Other autoimmune bowel disorder (651) – **Go to question 287**

175. Specify other arthritis: _____
176. Specify other juvenile idiopathic arthritis (JIA): _____
177. Specify other connective tissue disease: _____
178. Specify other vasculitis: _____
179. Specify other autoimmune neurological disorder: _____
180. Specify other autoimmune cytopenia: _____
181. Specify other autoimmune bowel disorder: _____

- Go to signature line

Other Disease

CIBMTR Center Number: _____ CIBMTR Research ID: _____

182. Specify other disease: _____

First Name: _____

Last Name: _____

E-mail address: _____

Date: _____
 YYYY MM DD

